200 related articles for article (PubMed ID: 12689934)
1. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
Linenberger ML; Hong T; Flowers D; Sievers EL; Gooley TA; Bennett JM; Berger MS; Leopold LH; Appelbaum FR; Bernstein ID
Blood; 2001 Aug; 98(4):988-94. PubMed ID: 11493443
[TBL] [Abstract][Full Text] [Related]
3. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
4. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.
Walter RB; Raden BW; Cronk MR; Bernstein ID; Appelbaum FR; Banker DE
Blood; 2004 Jun; 103(11):4276-84. PubMed ID: 14962898
[TBL] [Abstract][Full Text] [Related]
5. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
Yamauchi T; Matsuda Y; Tasaki T; Negoro E; Ikegaya S; Takagi K; Yoshida A; Urasaki Y; Ueda T
Cancer Sci; 2012 Sep; 103(9):1722-9. PubMed ID: 22632031
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
7. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
8. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
9. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
10. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
11. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
13. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.
Cianfriglia M; Mallano A; Ascione A; Dupuis ML
Int J Oncol; 2010 Jun; 36(6):1513-20. PubMed ID: 20428776
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
[TBL] [Abstract][Full Text] [Related]
15. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
16. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
Matsui H; Takeshita A; Naito K; Onishi K; Ono R
Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
[No Abstract] [Full Text] [Related]
17. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Giles F; Estey E; O'Brien S
Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
19. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]